Welcome to our dedicated page for NUGEN MEDICAL DEVICES news (Ticker: NGMDF), a resource for investors and traders seeking the latest updates and insights on NUGEN MEDICAL DEVICES stock.
NuGen Medical Devices Inc. (NGMDF) generates a steady flow of news around its needle-free subcutaneous drug-delivery technology, particularly the InsuJet™ needle-free insulin-delivery system. Company press releases highlight product launches, geographic expansion, distribution partnerships, financing events, leadership changes, and technology developments that shape NuGen’s role in the medical devices and diabetes-care space.
Recent news has focused on commercial rollouts and market access. NuGen has announced the Canada‑wide launch of InsuJet™, followed by expanded distribution across Canadian pharmacy retailers and distributors. In France, the company reported the launch of a dedicated French-language InsuJet™ e‑commerce platform developed with its exclusive distributor Sol‑Millennium France. In the United Kingdom and other territories, NuGen has disclosed a license, supply and distribution agreement with EziAutoJector® Limited and later reported NHS Drug Tariff approval for EziAutoJector® products based on NuGen’s needle-free technology.
NuGen’s news flow also covers technology and R&D milestones, including the development of a next-generation needle-free injection system featuring an internal sterile insulin cartridge protected by international patent WO2021206553. The company provides updates on this cartridge-based system alongside commentary on InsuJet™ clinical interest, such as recognition at the Société Francophone du Diabète congress and clinical evaluations at the Institut de Diabétologie et Nutrition du Centre.
Investors and observers can also follow corporate and financial developments, including the release of annual financial results, a strategic investment via secured convertible debentures from Sol‑Millennium Medical HK Limited and Nature Health Development (Hong Kong) Co. Limited, and associated board and leadership changes. For users tracking NGMDF, this news page offers a centralized view of NuGen’s commercial progress, partnerships, and product evolution in needle-free medical devices.
NuGen Medical Devices (TSXV:NGMDF) temporarily halted sales of certain devices in Canada after its Health Canada licence expired due to an untimely certificate renewal. This lapse is not a regulatory suspension or safety issue. A new licence application has been submitted and the company says communications with Health Canada are ongoing; global operations remain unaffected.
NuGen Medical Devices (TSXV: NGMDF) announced a change in senior finance leadership effective January 31, 2026. Veronique Laberge resigned as Chief Financial Officer and Corporate Secretary and Ajay Mishra was appointed to both roles. The company said Mr. Mishra will assume responsibility for financial reporting and related functions.
NuGen Medical Devices (TSXV: NGMDF) provided a 2025 year-end update outlining R&D, technical, clinical, and commercial progress across its needle-free subcutaneous drug-delivery programs.
Key 2025 achievements include feasibility of a Ready-to-Fill Nozzle, advancement of a next-generation variable-dose jet injector, pressure-profile optimization, prototype progress on a patented refill cartridge system, and development of an animal-use PetJet injector.
Operational expansions included a Netherlands design hub, two MedTech hires in China, clinical team growth in France, Brazil and Malaysia, formation of a Medical Advisory Board, UK launch of the EZIAUTOJECTOR with NHS Drug Tariff approval, and ongoing distributor and payer engagement in Mexico, Asia and Canada.
NuGen Medical Devices (TSXV: NGMD) has achieved a significant milestone as its UK distribution partner, EziAutoJector Ltd, received NHS Drug Tariff approval for its needle-free insulin delivery device. This approval means UK diabetes patients can receive the EziAutoJector device and accessories at no cost through NHS-funded care.
The company has established distribution channels through a major pharmaceutical wholesaler for both high-street and online pharmacies. The initiative includes educational programs targeting healthcare professionals and a direct-to-consumer e-commerce channel. Notably, each patient switching to EziAutoJector eliminates over 1,000 single-use insulin needles annually, supporting NHS environmental and cost-efficiency goals.
NuGen Medical Devices (TSXV: NGMD) has announced the development of a next-generation needle-free injection system featuring innovative internal cartridge technology. The system, protected under international patent WO2021206553, integrates a sterile internal insulin cartridge into their proprietary autoinjector.
The new design eliminates the need for external connectors and manual filling, offering improved safety and ease of use compared to current systems like InsuJet. Key technical features include an internal cartridge integration, backflow control mechanism, and enhanced usability.
Under CEO Liang Lin's leadership, NuGen plans to begin clinical investigations using their current platform while developing the new system. The company aims to produce working prototypes within six months and begin tooling investment in early 2026.
NuGen Medical Devices (TSXV: NGMD) has launched a French e-commerce platform www.insujet.fr for its needle-free insulin delivery device InsuJet. Developed with Sol-Millennium France, the platform offers product information, educational resources, and secure purchasing with optional nurse-led onboarding support.
The launch addresses a significant market opportunity in France, where 4.33 million people (6.3% of the population) lived with diabetes in 2022. Diabetes-related reimbursements in France increased from €7.6 billion in 2015 to over €10 billion in 2022. With 92% of Type 2 diabetes patients delaying insulin start due to needle anxiety, InsuJet aims to improve treatment adoption and reduce healthcare costs.
NuGen Medical Devices reported impressive financial results for 2024, marking a significant milestone in its commercial expansion. The company, known for needle-free therapeutic administration devices, achieved a remarkable 305% revenue increase and a 317% rise in gross profit.
Key financial highlights include a 31% reduction in selling, general and administrative expenses, and a 36% decrease in operational losses. The company successfully improved its balance sheet through debt renegotiation and secured a $10 million convertible debentures private placement in Q3. Working capital improved significantly to $6,466,218, compared to a negative $1,960,731 in 2023.
The company's InsuJet™ sales contributed to this record-breaking year, with Q4 shipments fulfilling previously announced orders. Management expects continued growth in 2025, focusing on expansion in Canada and Europe while investing in product development to enhance patient care outcomes.
NuGen Medical Devices (TSXV: NGMD) announces expanded distribution of its InsuJet™ needle-free insulin delivery device across Canada following Health Canada approval and nationwide introduction in November 2024.
The device is now available through major pharmacy retailers including London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart, and McKesson Canada. New partnerships with Kohl & Frisch and a national retail partner will begin mid-April 2025.
The company's Canadian distributor, Sol-Millennium, has partnered with MyRxCare and Greenshield Canada for pharmacy adjudication and educational support. Additionally, they continue collaboration with I Challenge Diabetes, whose CEO Chris Jarvis promotes the technology nationwide. Sol-Millennium is actively participating in various healthcare conferences throughout 2025 to engage with healthcare professionals and promote the benefits of InsuJet™.
NuGen Medical Devices has appointed Liang Lin as its new Chief Executive Officer. Lin, who joined NuGen's board in September 2024 following Sol-Millennium Medical Group's (SolM) strategic investment, brings extensive experience in the medical device sector. As the founder and CEO of SolM, Lin has demonstrated success in expanding international operations, particularly in North America and Brazil through strategic acquisitions.
Under Lin's leadership, SolM has established offices across Europe and the Middle East, invested in R&D facilities in Asia and Europe, and developed innovative medical devices. Lin replaces Karen Dunlap, who served as Interim CEO and will continue with the company as director and Chief Customer Officer. In his new role, Lin aims to leverage his industry expertise to drive global sales growth and meet anticipated InsuJet™ production demands for 2025.
NuGen Medical Devices has launched InsuJet™, its needle-free therapeutic administration device, across Canada. The company received orders for 3,250 InsuJet™ starter kits and consumables, generating revenue of $670,000 with a gross margin of $368,500 in Q3 and Q4 2024. The launch began on November 15, coinciding with World Diabetes Day celebrations at Banting House in London, Ontario. Major pharmacy networks including London Drugs, Pharmasave, and others will distribute InsuJet™ through distributors like McKesson Canada and UniPharm, making it accessible to all 12,000 pharmacies across Canada. InsuJet™ is currently approved in 42 countries.